219 related articles for article (PubMed ID: 18687352)
1. How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review.
Kenyon EM; Klimecki WT; El-Masri H; Conolly RB; Clewell HJ; Beck BD
Toxicol Appl Pharmacol; 2008 Nov; 232(3):359-68. PubMed ID: 18687352
[TBL] [Abstract][Full Text] [Related]
2. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
[TBL] [Abstract][Full Text] [Related]
3. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
Kitchin KT; Conolly R
Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
[TBL] [Abstract][Full Text] [Related]
4. Research approaches to address uncertainties in the risk assessment of arsenic in drinking water.
Hughes MF; Kenyon EM; Kitchin KT
Toxicol Appl Pharmacol; 2007 Aug; 222(3):399-404. PubMed ID: 17379267
[TBL] [Abstract][Full Text] [Related]
5. Dynamical coupling of PBPK/PD and AUC-based toxicity models for arsenic in tilapia Oreochromis mossambicus from blackfoot disease area in Taiwan.
Liao CM; Liang HM; Chen BC; Singh S; Tsai JW; Chou YH; Lin WT
Environ Pollut; 2005 May; 135(2):221-33. PubMed ID: 15734582
[TBL] [Abstract][Full Text] [Related]
6. Molecular processes in cellular arsenic metabolism.
Thomas DJ
Toxicol Appl Pharmacol; 2007 Aug; 222(3):365-73. PubMed ID: 17397889
[TBL] [Abstract][Full Text] [Related]
7. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
9. Workshop overview: arsenic research and risk assessment.
Sams R; Wolf DC; Ramasamy S; Ohanian E; Chen J; Lowit A
Toxicol Appl Pharmacol; 2007 Aug; 222(3):245-51. PubMed ID: 17336359
[TBL] [Abstract][Full Text] [Related]
10. A dose-based modeling approach for accumulation and toxicity of arsenic in tilapia Oreochromis mossambicus.
Tsai JW; Liao CM
Environ Toxicol; 2006 Feb; 21(1):8-21. PubMed ID: 16463258
[TBL] [Abstract][Full Text] [Related]
11. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure.
Liao CM; Shen HH; Chen CL; Hsu LI; Lin TL; Chen SC; Chen CJ
J Hazard Mater; 2009 Jun; 165(1-3):652-63. PubMed ID: 19062162
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
13. Research strategy for developing key information on bromate's mode of action.
Bull RJ; Cottruvo JA
Toxicology; 2006 Apr; 221(2-3):135-44. PubMed ID: 16298034
[TBL] [Abstract][Full Text] [Related]
14. A physiologically based pharmacokinetic model of inorganic arsenic.
Yu D
Regul Toxicol Pharmacol; 1999 Apr; 29(2 Pt 1):128-41. PubMed ID: 10341143
[TBL] [Abstract][Full Text] [Related]
15. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment.
Clark LH; Setzer RW; Barton HA
Risk Anal; 2004 Dec; 24(6):1697-717. PubMed ID: 15660623
[TBL] [Abstract][Full Text] [Related]
16. Bioenergetics-based matrix population modeling enhances life-cycle toxicity assessment of tilapia Oreochromis mossambicus exposed to arsenic.
Liao CM; Chiang KC; Tsai JW
Environ Toxicol; 2006 Apr; 21(2):154-65. PubMed ID: 16528691
[TBL] [Abstract][Full Text] [Related]
17. Appropriate use of animal models in the assessment of risk during prenatal development: an illustration using inorganic arsenic.
Holson JF; Desesso JM; Jacobson CF; Farr CH
Teratology; 2000 Jul; 62(1):51-71. PubMed ID: 10861633
[TBL] [Abstract][Full Text] [Related]
18. A human PBPK/PD model to assess arsenic exposure risk through farmed tilapia consumption.
Ling MP; Liao CM
Bull Environ Contam Toxicol; 2009 Jul; 83(1):108-14. PubMed ID: 19452117
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
[TBL] [Abstract][Full Text] [Related]
20. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans.
Mann S; Droz PO; Vahter M
Toxicol Appl Pharmacol; 1996 Oct; 140(2):471-86. PubMed ID: 8887465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
